Hengrui Medicine (01276.HK) announced that it has received approval from the National Medical Products Administration for the clinical trials of SHR2554 tablets, SHR-A1811 injection, SHR-A2102 injection, Ademabali monoclonal antibody injection, SHR-A1904 injection, and SHR-1701 injection, which will begin clinical trials soon.
The group indicated that to date, the cumulative R&D investment for SHR2554 tablet-related projects is approximately 0.179 billion yuan (RMB, same below), for SHR-A1811 injection-related projects is approximately 1.17 billion yuan; for SHR-A2102 injection-related projects is approximately 0.205 billion yuan; for Ademabali monoclonal antibody injection-related projects is approximately 0.887 billion yuan; for SHR-A1904 injection-related projects is approximately 0.143 billion yuan; for SHR-1701 injection-related projects is approximately 0.674 billion yuan.
